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Providing medicine for paediatric patients is a huge 
challenge, including the lack of information on drug 
dosages and the availability of dosage to form the 
formulas. Medication errors and serious risks are also 
more common in children than adults (C. 
Wiedyaningsih et al., 2012). Besides, the need for 
treatment in paediatric patients is certainly not the 
same as in adults because the physiology of the 
paediatric patients’ bodies must be considered 
different in terms of pharmacokinetics, dosage, route 
of administration and adherence. That is the reason 
why a study for paediatric medication is required. 
An extemporaneous preparation or compounded drug 
is commonly used as a medication for paediatrics 
(Widyaswari & Wiedyaningsih, 2012). Compounding is 
an activity of changing dosage form or mixing drugs into 
a new dosage form which is needed for the patient 
(Jackson & Lowey, 2010). It has a high risk and should 
be of concern because there are many undesirable 
events such as pharmaceutical problems, drug 
interactions, medication errors, quality of concoctions, 
and bacterial contamination problems.  However, drug 
compounding is generally a solution to the limitation of 
drug formulas for paediatrics (C. Wiedyaningsih et al., 
2012). 
There are some alternatives to drug compounding for 
paediatric patients. Divided medicinal powder, syrup, 
dispersible powder/tablet, etc., are some dosage 
formulations that are commonly used. The study from 
Virginia (2014) showed that 73% of paediatric patients 
were more likely to get divided medicinal powder as a 
medication. Divided medicinal powder, also known as 
“puyer” in Indonesia, has several advantages, such as 
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Introduction: The availability of licensed drug formulas for paediatric patients is still limited, so 
compounded drugs still exist, especially in the form of divided medicinal powder.  Aim: This study 
aimed to determine the profile of divided medicinal powder prescription and its availability in 
licensed drug formula for paediatric patients.  Methods: This research was a cross-sectional study. 
Prescriptions containing order to compound divided medicinal powder at a ublic Hospital in 
Yogyakarta Special Region from January to March 2019, were collected and analysed descriptively. 
Results: The total collected prescriptions were 152.  The total of active substances given to 
paediatric patients was 38. The most prescribed drug in the hospital was Triamcinolone. There are 
34 active substances already available in licensed drug formulas for paediatric patients, so it is better 
not to be compounded. However, four active substances are not available as licensed product in 
the drug information handbook in Indonesia, so, it is reasonable to compound to provide a suitable 
medication (dose and dosage form) for paediatric patients. 
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simplicity to use (Virginia, 2014). However, it also has 
some disadvantages, including the possibility of 
adverse events, drug interactions, incompatibilities, 
and other risks (Rochjana et al., 2019).  
A study of the profile and determinants of 
compounding services in the Yogyakarta Special Region 
showed that most community pharmacists (94%) 
dispensed prescriptions with compounding.  
Prescription-required compounding accounted for 
11.55% of prescriptions dispensed within one month 
(Kristina et al., 2018). There is a high risk of medication 
error with compounding. This high compounding 
frequency rate and its risk make it important to do 
research on the profile of the compounding 
prescription in every health facility. The risk and 
negative effects of drug compounding should be 
minimised by using a licensed product for paediatric 
medication. Thus, it is necessary to carry out an analysis 
of the availability of licensed products for medicines 
formulated in a pharmaceutical installation. Studies 
have been conducted regarding the profile of the 
compounding prescription and also the evaluation of its 
availability as licensed products in a primary health 
facility in Yogyakarta (Widyaswari & Wiedyaningsih, 
2012). In that study, it was found that there are still 
some drugs intended for children, not available in the 
form of a licensed formula. 
This study aimed to determine and evaluate the 
compounding prescription profile, especially in divided 
medicinal powder form, and its availability as a licensed 
product in a public hospital in Yogyakarta Special 
Region. The results of this study are expected to 
provide long-term benefits in decreasing the frequency 
of compounding drugs for active substances available 
in licensed dosage forms for children. 
 
Methods 
This study was an analytical observation with a 
retrospective cross-sectional design. This study had an 
ethical clearance certificate from the Ethical 
Commission of the University of Respati Yogyakarta, no 
130.3/FIKES/PL/V/2019. The population were all 
prescribed medicines in the hospital. The samples of 
prescriptions were collected by purposive sampling 
method in a pharmacy department at a public hospital 
in Yogyakarta Special Region. The inclusion criteria for 
the sample was that prescriptions contain an order to 
compound the divided medicinal powder for paediatric 
patients (0-18 years old) from January to March 2019. 
The exclusion criteria were unreadable prescriptions 
(illegible handwriting).  
After the data were collected, they were analysed 
descriptively into two sections, including: 
a. The profile of divided medicinal powder 
prescription:  
The profile analysis of prescription includes the 
characteristics of the subject, the age, the number 
of compounding, and the number of active 
substances contained in the preparations. The data 
were analysed descriptively and presented in the 
form of tabulation of frequency and percentage. 
b. The analysis of the availability of a licensed product 
for paediatric patients: 
The availability of the licensed product for paediatric 
patients (syrups, dry syrups, powder drops, 
suspensions, lozenges, and chewable tablets) was seen 
from the literature. The literature was MIMS 
Consultation Guidelines 2019/2020 and ISO Indonesia 
volume 52 (2019).  
 
Results 
In this study, the profile of divided medicinal powder 
prescriptions was analysed from all prescriptions that 
met the inclusion criteria. There are 152 prescriptions 
from the observation. In Figure 1, the profile of the 
subject was clearly shown that compounded drug was 
highly prescribed for paediatrics under five years old. 
Meanwhile, there are about 3% of the patients with the 
age range 12-18 years old also get a divided medicinal 
powder. 
 
Figure 1: The profile of compounding prescription 
 
The number of active substances that were 
compounded in one dosage form was also analysed. It 
was shown that more than half of all compounded 
drugs were containing one active substance. The 
highest number of active ingredients containing in a 
prescription were five substances; this kind of 
prescription-only appear in a low frequency (2%). 
The availability of the licensed product for paediatric 
patients was analysed from all the active substances 
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prescriptions obtained; there are 38 active substances 
prescribed for compounding (Table I). The top five 
frequently prescribed were Triamcinolone, 
Phenobarbital, Salbutamol Sulfate, Levotiroksin 
sodium, and Bromheksin. Most of them were drugs 
that indicated respiratory disease. 
 
Table I: Active substances that undergo compounding along with the frequency of prescription 
Active substances Frequency Percentage Active substances Frequency Percentage 
Triamcinolone 45 17.65 % Ambroxol HCl 2 0.78 % 
Phenobarbital 30 11.76 % Methylprednisolone 2 0.78 % 
Salbutamol Sulfate 25 9.80 % Loratadine 2 0.78 % 
Levotiroksin Sodium 17 6.66 % Lisinopril 2 0.78 % 
Bromheksin 15 5.88 % Spironolactone 2 0.78 % 
Terfenadine 12 4.70 % Triheksiphenidil 2 0.78 % 
Pseudoephedrine HCl 12 4.70 % Ursodeoksikolat 2 0.78 % 
Captopril 10 3.92 % Risperidone 2 0.78 % 
Piracetam 9 3.52 % Vitamin B6 (Pyridoxine) 1 0.39 % 
Furosemide 9 3.52 % Ranitidine 1 0.39 % 
Cefixime 9 3.52 % Alprazolam 1 0.39 % 
Phenytoine 7 2.74 % Buspirone 1 0.39 % 
Cetirizine 5 1.96 % Haloperidol 1 0.39 % 
Asam Folat 5 1.96 % Amoxicillin 1 0.39 % 
Diazepam 4 1.56 % Mebendazole 1 0.39 % 
Mebhydrolin  4 1.56 % Clindamicin 1 0.39 % 
Vitamin B1 (Thiamin) 4 1.56 % Clobazam 1 0.39 % 
Paracetamol 3 1.17 % Levotiroksin 1 0.39 % 




The profile of divided medical powder prescriptions 
was analysed from the subject (patients) and the object 
(drug). In this study, 152 prescriptions suited the 
inclusion criteria to analyse its profile. The profile of the 
prescription was presented in Figure 1. It was shown 
that children from 0-5 years old were likely to get a 
divided medicinal powder as the medication. It is 
reasonable because, at those ages, they may have 
difficulty in taking a tablet or comply when given more 
than one drug (dosage form). Besides, the licensed 
product is also considered expensive (Setyani & Putri, 
2019; C. Wiedyaningsih et al., 2012). This phenomenon 
was also shown in a study by Piliarta (2012), which 
stated that children under five years old tended to get 
compounded drugs than the older children (Piliarta et 
al., 2012). Meanwhile, there are about 3% of the 
patients with the age range 12-18 years old also get a 
divided medicinal powder. At this age, children should 
be able to get a pill or tablet as a medicine to reduce 
the number of compounded drugs. 
The divided medicine powder can contain one or more 
active substances, which are mixed into one dosage 
form. The amount of active substances given to the 
patient depends on the severity and the doctor's 
diagnosis based on the symptoms and condition of the 
patient (C. Wiedyaningsih et al., 2012). An analysis of 
the number of active substances in each prescription is 
useful to evaluate the prescription profile. There were 
62% of prescriptions that were prepared with only one 
active substance. As seen in Figure 1b, the 
compounding order containing five active substances 
had the lowest frequency. This result shows that 
compounding practice in the hospital has compromised 
the potency of the compounded drug, thus increasing 
incompatibility and instability. The incompatibility and 
instability in the compounded drug will increase as 
more active substances are added (Setyani & Putri, 
2019; C. Wiedyaningsih et al., 2012). 
Compounding drugs using one type of active substance 
is usually carried out for several reasons, such as 
because of the limited licensed preparations for 
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children (syrup, drop) or because the available licensed 
preparations are not affordable (Setyani & Putri, 2019). 
In this study, the active substances that were 
compounded were recorded, and their frequency was 
calculated. From the 152 collected prescriptions, 38 
active substances were compounded (Table I). These 
active substances were then examined for their 
availability in licensed products for paediatric patients.  
Based on Table I, the five types of active substances 
mostly compounded into divided medicine powder 
were Triamcinolone acetonide as an anti-inflammatory 
drug, Phenobarbital as antiepileptic, Salbutamol as an 
anti-asthmatic drug, Levotiroxin Na as an antithyroid 
drug to treat hyperthyroidism, and Bromhexine as a 
mucolytic agent. In March 2020, it appeared that there 
are certain drug prescriptions that are higher than 
other months. It is because the weather and climatic 
condition in Yogyakarta Special Region from January to 
March 2020 was cold and rainy. It caused the children 
with low immunity to have a common cold, asthma, 
rhinitis allergic, etc. It was reasonable that these drugs 
have a high prescribing frequency. The results of this 
study are in line with the research of Wiedyaningsih 
and Oetari (2005), who also found that compounded 
drugs are prescribed primarily for the purpose of 
treating respiratory diseases and allergies.(Chairun & 
Wiedyaningsih. 2005). 
The availability of licensed products for paediatric 
patients was analysed from all the active substances 
that were compounded. The results showed that from 
152 prescriptions obtained,  38 active substances were 
prescribed for compounding (Table 1). The evaluation 
of their availability in licensed products for paediatrics 
based on the literature (MIMS Consultation Guidelines 
2019/2020 and ISO Indonesia volume 52 (2019) 
showed that four drugs were not available for 
paediatrics. Specifically, these drugs were not available 
in a single composition with a suitable dosage form for 
children, and there was no available information on the 
paediatric dose. These four drugs were Thiamin, Niacin, 
Pyridoxine, and Buspirone. However, the other active 
substances that were available in licensed products 
were still compounded.  
There are some limitations in this study that might be 
improved. Observation for the reason to compound the 
drug from the doctor should also be considered in this 
study. It will give more information why a lot of drug 
which already available in the licensed product was still 
compounded. Drug compounding has some issues 
about the stability of the compounded products, the 
accuracy in dose strength, and the lack of standard 
protocol (Gudeman et al., 2013; Kristina et al., 2017). 
The pharmacy department should conduct a risk 
assessment of active substances that are routinely used 
or have a high frequency of compounding. It may 
prevent medication errors in the dispensing stage. If 
the results of the risk assessment and risk analysis show 
that there is a potential risk (either related to quality, 
efficacy, or safety) to the compounded drugs, it will be 
better if the drugs are delivered with the available 
licensed products to minimise or eliminate the risks 
(Jackson & Lowey, 2010). 
 
Conclusion 
The profile of divided medical powder prescriptions in 
this hospital from January to March 2020 were mostly 
written for paediatrics patients under five years old. 
The most compounded drug contained one active 
substance. There are 34 active substances available as 
licensed products for children. However, there are four 
active substances that are not available as licensed 
products for children, namely Thiamin, Niacin, 
Pyridoxine, and Buspirone. The results of this study are 
very useful for hospitals to identify what drugs are 
actually available in licensed products, to minimise the 
frequency of compounding and reduce the risk of 
medication errors in drug compounding. To minimise 
the risk of errors at the dispensing stage, it is 
recommended that these 34 active substances are 
delivered in available licensed products. 
Comprehensive research is needed to better describe 
the profile of compounding prescription, so it can assist 
pharmacists in hospitals in formulating strategic steps 
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